Novartis Reports Results of Kisqali in Second Phase P-III MONALEESA-3 Study for HR+/HER2- Advanced Breast Cancer in Women

 Novartis Reports Results of Kisqali in Second Phase P-III MONALEESA-3 Study for HR+/HER2- Advanced Breast Cancer in Women

Shots:

  • The P-III MONALEESA-3 study involves assessing of Kisqali (ribociclib) + fulvestrant in postmenopausal women with HR+/HER2- advanced or m-breast cancer
  • The second phase of P-III MONALEESA-3 study resulted in meeting its 2EPs of OS with no new observed safety signals and consistent AEs with the previous P-III study results. These results follow MONALEESA-7 study results which demonstrated improved OS in patients with HR+/HER2- advanced breast cancer in pre/peri-menopausal women
  • Kisqali is the CDK4/6 inhibitor, being evaluated in P-III NATALEE study with endocrine therapy in the adjuvant treatment of HR+/HER2- early breast cancer and has received FDA & EMA’s approval in Mar’2017 and Aug’2017 respectively

Click here to­ read full press release/ article | Ref: Novartis | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post